Specialty Pharmacy

Symtuza (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg) offers a new treatment option to adults living with HIV.

Study finds that specialty drug coverage policies are mostly inconsistent across health plans and many treatments have multiple restrictions to access.

Supplementation of the protein in the nerve cells prevented nerve degeneration, muscle atrophy, and paralysis in an amyloid lateral sclerosis mouse model.

Top news of the day from across the health care landscape.

New research has identified the origins of acute myeloid leukemia, which can be detectable more than 5 years before the disease develops.

Health care providers who offer HIV tests encourage patients to integrate preventive screenings into their health care routines.

Individuals treated for cancer in adolescence or young adulthood may be at higher risk for endocrine diseases, such as thyroid disease, testicular dysfunction, and diabetes.

Most individuals with multiple sclerosis experience pain as a symptom of the disease.

Top news of the day from across the health care landscape.

A new study provides insight into previously unknown details about the capsid that may have implications for the development of new drugs to treat the infection.

Officials with the US FDA are alerting health care professionals and patients of a voluntary recall of several, but not all, drug products containing the active ingredient valsartan.

Enzalutamide (Xtandi) is the first and only FDA-approved oral medication for both non-metastatic and metastatic castration-resistant prostate cancer.

Officials with the FDA have approved tecovirimat (TPOXX, SIGA), the first drug with an indication for the treatment of smallpox, to boost preparedness in the event of a bioterror attack

Study suggests that covering high-value medications benefits patients at no extra cost to insurers.

Researchers aim to determine whether an annual brain volume loss rate of less than 0.4% is a valid marker to assess treatment response.

Top news of the day from across the health care landscape.

The discontinuation of opioid therapy may address the rising death toll caused by drug overdoses while maintaining or potentially improving chronic, non-cancer pain in patients, according to a recent study.

Ron Lanton III, Esq., executive director and senior counsel for Frier Levitt Government Affairs, discusses how to boost prescriber uptake of biosimilars.

Cognitive impairment is present in up to 70% of patients with multiple sclerosis, but can be difficult to completely evaluate in routine clinical practice.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

The FDA has issued disease-specific draft guidances for the development of gene therapies for certain conditions.

Mobile health interventions have the potential to help people living with HIV improve engagement in care, promote medication adherence, and in turn, improve patient outcomes.

A look at last week's top stories in the world of pharmacy.

Nivolumab (Opdivo) plus ipilimumab (Yervoy) approved for patients with microsatellite instability high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

Research to explore whether intermittent fasting can improve symptoms in patients with relapsing-remitting multiple sclerosis.

Olaparib (Lynparza, Merck and AstraZeneca) demonstrated significant improvement in progression-free survival in the first-line maintenance setting for women with advanced BRCA-mutated ovarian cancer.

Top news of the day from across the health care landscape.

Hepatocellular carcinoma is the most common type of liver cancer in adults.

Even as fewer patients are using them, the 10 medications with the highest spend in Medicare Part D have seen substantial increases in spending and out-of-pocket costs.